1. Home
  2. OPTH vs GRML Comparison

OPTH vs GRML Comparison

Compare OPTH & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Optimi Health Corp. Common Shares

OPTH

Optimi Health Corp. Common Shares

HOLD

Current Price

$3.25

Market Cap

28.9M

Sector

N/A

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

HOLD

Current Price

$5.86

Market Cap

29.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPTH
GRML
Founded
2020
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
29.2M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
OPTH
GRML
Price
$3.25
$5.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.4K
★ 6.0M
Earning Date
12-08-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.25
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.17
N/A
Revenue Next Year
$82.70
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.04
$0.16
52 Week High
$5.45
$18.21

Technical Indicators

Market Signals
Indicator
OPTH
GRML
Relative Strength Index (RSI) 27.97 47.10
Support Level $3.04 $0.28
Resistance Level $5.21 $7.53
Average True Range (ATR) 0.32 0.85
MACD -0.04 -0.28
Stochastic Oscillator 10.00 34.48

Price Performance

Historical Comparison
OPTH
GRML

About OPTH Optimi Health Corp. Common Shares

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: